Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0M2WQ
|
|||
Former ID |
DIB004367
|
|||
Drug Name |
CAP-7.1
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
Company |
CellAct Pharma GmbH
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C36H42O17
|
|||
Canonical SMILES |
CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OC(=O)OCC8COC(O8)(C)C)OC)O)O
|
|||
InChI |
1S/C36H42O17/c1-15-43-13-25-32(49-15)28(37)29(38)34(50-25)51-30-19-9-22-21(46-14-47-22)8-18(19)26(27-20(30)12-44-33(27)39)16-6-23(41-4)31(24(7-16)42-5)52-35(40)45-10-17-11-48-36(2,3)53-17/h6-9,15,17,20,25-30,32,34,37-38H,10-14H2,1-5H3/t15?,17?,20-,25+,26+,27-,28+,29+,30+,32+,34-/m0/s1
|
|||
InChIKey |
FCWSQAKOPTZCOD-OUCIFNFRSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02094560) CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors. U.S. National Institutes of Health. | |||
REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.